| WANBURY  Financial Statement Analysis | ||
| The Revenues of WANBURY  have increased by 3.77% YoY . The Earnings Per Share (EPS) of WANBURY has decreased by -45.47 % YoY. | ||
| REVENUES | 
| OPERATING MARGIN | 
| PROFIT AFTER TAX | 
| EPS | 
| ROCE | 
WANBURY  Last 5 Annual Financial Results
 [BOM: 524212|NSE : WANBURY] 
            | Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | 
|---|---|---|---|---|---|
| Revenues | ₹600 Cr | ₹578 Cr | ₹500 Cr | ₹511 Cr | ₹393 Cr | 
| Expenses | ₹532 Cr | ₹506 Cr | ₹477 Cr | ₹479 Cr | ₹377 Cr | 
| Operating Profit (Excl OI) | ₹68 Cr | ₹72 Cr | ₹23 Cr | ₹32 Cr | ₹16 Cr | 
| Other Income | ₹12 Cr | ₹0.90 Cr | ₹1.01 Cr | ₹5.09 Cr | ₹4.75 Cr | 
| Interest | ₹37 Cr | ₹29 Cr | ₹21 Cr | ₹21 Cr | ₹23 Cr | 
| Depreciation | ₹13 Cr | ₹13 Cr | ₹12 Cr | ₹11 Cr | ₹9.75 Cr | 
| Profit Before Tax | ₹30 Cr | ₹56 Cr | ₹-10 Cr | ₹81 Cr | ₹-12 Cr | 
| Profit After Tax | ₹31 Cr | ₹56 Cr | ₹-10 Cr | ₹81 Cr | ₹-13 Cr | 
| Consolidated Net Profit | ₹31 Cr | ₹56 Cr | ₹-10 Cr | ₹81 Cr | ₹-13 Cr | 
| Earnings Per Share (Rs) | ₹9.32 | ₹17.09 | ₹-3.18 | ₹24.94 | ₹-5.04 | 
| PAT Margin (%) | 5.06 | 9.60 | -2.04 | 15.83 | -3.20 | 
| ROE(%) | 84.21 | 0.00 | 0.00 | 0.00 | 0.00 | 
| ROCE(%) | 35.97 | 101.56 | 29.82 | 428.78 | 87.61 | 
| Total Debt/Equity(x) | 3.37 | 5.18 | -1.86 | -2.72 | -1.02 | 
| Key Financials | ||
| Market Cap | : | ₹ 918.4 Cr | 
| Revenue (TTM) | : | ₹ 629.8 Cr | 
| Net Profit(TTM) | : | ₹ 43.0 Cr | 
| EPS (TTM) | : | ₹ 12.3 | 
| P/E (TTM) | : | 21.4 | 
| Industry Peers & Returns | 1W | 1M | 1Y | 
| WANBURY | 3.5% | 3.4% | 15.4% | 
| SUN PHARMACEUTICAL INDUSTRIES | -0.3% | 6% | -10.5% | 
| DIVIS LABORATORIES | 3.9% | 18.6% | 14.5% | 
| CIPLA | -5.2% | NA | 2.5% | 
| TORRENT PHARMACEUTICALS | -1% | -1.2% | 8.7% | 
| DR REDDYS LABORATORIES | -6.8% | -2.1% | -8.4% | 
| MANKIND PHARMA | -1.4% | -2.2% | 0.7% | 
| ZYDUS LIFESCIENCES | -3.9% | -0.7% | -2% | 
| LUPIN | 2.2% | 2.8% | -11.8% | 
WANBURY  Revenues
 [BOM: 524212|NSE : WANBURY]  
                        | Y-o-Y | 3.77 % | 
| 5 Yr CAGR | 11.17 % | 
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹600 Cr | 3.77 | |
| Mar2024 | ₹578 Cr | 15.63 | |
| Mar2023 | ₹500 Cr | -2.26 | |
| Mar2022 | ₹511 Cr | 30.23 | |
| Mar2021 | ₹393 Cr | - | |
WANBURY  Operating Profit
 [BOM: 524212|NSE : WANBURY]  
                    | Y-o-Y | -6.10 % | 
| 5 Yr CAGR | 44.17 % | 
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹68 Cr | -6.10 | |
| Mar2024 | ₹72 Cr | 212.39 | |
| Mar2023 | ₹23 Cr | -27.28 | |
| Mar2022 | ₹32 Cr | 102.52 | |
| Mar2021 | ₹16 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -9.54 % | 
| 5 Yr CAGR | 29.70 % | 
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 11.29% | -9.54 | |
| Mar2024 | 12.48% | 170.13 | |
| Mar2023 | 4.62% | -25.60 | |
| Mar2022 | 6.21% | 55.64 | |
| Mar2021 | 3.99% | - | |
WANBURY  Profit After Tax
 [BOM: 524212|NSE : WANBURY]  
            | Y-o-Y | -45.44 % | 
| 5 Yr CAGR | Positive | 
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹31 Cr | -45.44 | |
| Mar2024 | ₹56 Cr | Positive | |
| Mar2023 | ₹-10 Cr | Negative | |
| Mar2022 | ₹81 Cr | Positive | |
| Mar2021 | ₹-13 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -47.29 % | 
| 5 Yr CAGR | Positive | 
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 5.06 % | -47.29 | |
| Mar2024 | 9.6 % | Positive | |
| Mar2023 | -2.04 % | Negative | |
| Mar2022 | 15.83 % | Positive | |
| Mar2021 | -3.2 % | - | |
WANBURY  Earnings Per Share (EPS)
 [BOM: 524212|NSE : WANBURY]  
            | Y-o-Y | -45.47 % | 
| 5 Yr CAGR | Positive | 
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹9.32 | -45.47 | |
| Mar2024 | ₹17 | Positive | |
| Mar2023 | ₹-3.18 | Negative | |
| Mar2022 | ₹25 | Positive | |
| Mar2021 | ₹-5.04 | - | |
WANBURY  Return on Capital Employed (ROCE)
 [BOM: 524212|NSE : WANBURY]  
            | Y-o-Y | -64.58 % | 
| 5 Yr CAGR | -19.95 % | 
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 35.97% | -64.58 | |
| Mar2024 | 101.56% | 240.58 | |
| Mar2023 | 29.82% | -93.05 | |
| Mar2022 | 428.78% | 389.42 | |
| Mar2021 | 87.61% | - | |
WANBURY Share Price vs Sensex
| Current Share Price | : | ₹263.2 | 
| Current MarketCap | : | ₹ 918.4 Cr | 
| Updated EOD on | : | Oct 31,2025 | 
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year | 
| WANBURY | 3.5% | 3.4% | 15.4% | 
| SENSEX | -0.3% | 4.5% | 5.7% | 
WANBURY related INDICES
| BSE Indices | 1W | 1M | 1Y | 
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% | 
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% | 
| BSE SMALLCAP | 0.7% | 3.2% | 2.9% | 
| BSE HEALTHCARE | -0.8% | 3.3% | 4% | 
You may also like the below Video Courses
FAQ about WANBURY Financials
How the annual revenues of WANBURY have changed ?
The Revenues of WANBURY have increased by 3.77% YoY .
How the Earnings per Share (EPS) of WANBURY have changed?
The Earnings Per Share (EPS) of WANBURY has decreased by -45.47 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
 
                     
                                     
                                     
                                    